Modality
Small Molecule
MOA
BETi
Target
PLK4
Pathway
Cell Cycle
PsoriasisDLBCLUC
Development Pipeline
Preclinical
Nov 2024
→ Jan 2028
PreclinicalCurrent
NCT04993256
420 pts·DLBCL
2024-11→2028-01·Recruiting
420 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-161.8y awayInterim· DLBCL
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Recruit…
Catalysts
Interim
2028-01-16 · 1.8y away
DLBCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04993256 | Preclinical | DLBCL | Recruiting | 420 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 |